Gemcitabine plus nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: A population-based, multicenter AGEO study

被引：1
|
作者：
Zaibet, S. [1 ]
Hautefeuille, V. [2 ]
Auclin, E. [1 ]
Lievre, A. [3 ]
Tougeron, D. [4 ,5 ]
Sarabi, M. [6 ]
Gilabert, M. [7 ]
Wasselin, J.
Edeline, J. [8 ]
Artru, P. [9 ]
Bechade, D. [10 ]
Morin, C. [6 ]
Taieb, J. [11 ]
Pernot, S. [10 ]
机构：
[1] AP HP, Paris, France
[2] CHU Amiens, Amiens, France
[3] CHU Rennes, Rennes, France
[4] Univ Poitiers Hosp, Gastroenterol Dept, Poitiers, France
[5] Univ Poitiers, Poitiers, France
[6] Ctr Leon Berard, Lyon, France
[7] Inst Paoli Calmettes, Marseille, France
[8] Ctr Eugene Marquis, Rennes, France
[9] Hop Prive Jean Mermoz, Lyon, France
[10] Inst Bergonie, Bordeaux, France
[11] Paris Descartes Univ, Georges Pompidou European Hosp, Sorbonne Paris Cite, Paris, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.04.462
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD-6
引用
收藏
页码：S213 / S214
页数：2
相关论文
共 50 条
  • [41] ECONOMIC EVALUATION OF NAB-PACLITAXEL PLUS GEMCITABINE VERSUS GEMCITABINE ALONE FOR THE MANAGEMENT OF METASTATIC PANCREATIC CANCER IN GREECE
    Fragoulakis, V
    Papakostas, P.
    Pentheroudakis, G.
    Dervenis, C.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A632 - A632
  • [42] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Fukahori, Masaru
    Okabe, Yoshinobu
    Shimokawa, Mototsugu
    Otsuka, Taiga
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Makiyama, Akitaka
    Taguchi, Hiroki
    Honda, Takuya
    Ushijima, Tomoyuki
    Miwa, Keisuke
    Shibuki, Taro
    Nio, Kenta
    Ide, Yasushi
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [43] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Wang, Ying
    Camateros, Pierre
    Cheung, Winson Y.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (01) : 62 - 68
  • [44] Comparative effectiveness of gemcitabine vs gemcitabine plus nab-paclitaxel vs FOLFIRINOX for unresectable pancreatic cancer
    Yamamoto, Shun
    Ueno, Hideki
    Tanaka, Midori
    Inagaki, Yuji
    Ohba, Akihiro
    Sakamoto, Yasunari
    Kondo, Shunsuke
    Morizane, Chigusa
    Okusaka, Takuji
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer
    Masaru Fukahori
    Yoshinobu Okabe
    Mototsugu Shimokawa
    Taiga Otsuka
    Futa Koga
    Yujiro Ueda
    Junichi Nakazawa
    Azusa Komori
    Satoshi Otsu
    Shiho Arima
    Akitaka Makiyama
    Hiroki Taguchi
    Takuya Honda
    Tomoyuki Ushijima
    Keisuke Miwa
    Taro Shibuki
    Kenta Nio
    Yasushi Ide
    Norio Ureshino
    Toshihiko Mizuta
    Kenji Mitsugi
    Tsuyoshi Shirakawa
    Scientific Reports, 13
  • [46] Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis
    Chae, Heejung
    Jeong, Hyehyun
    Cheon, Jaekyung
    Chon, Hong Jae
    Ryu, Hyewon
    Kim, Il-Hwan
    Kang, Myoung Joo
    Jeong, Jae Ho
    Ryoo, Baek-Yeol
    Kim, Kyu-pyo
    Yoo, Changhoon
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [47] A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers
    Ying Wang
    Pierre Camateros
    Winson Y. Cheung
    Journal of Gastrointestinal Cancer, 2019, 50 : 62 - 68
  • [48] Retrospective analysis of institutional outcomes with FOLFIRINOX versus nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Singh, Amisha
    Shroff, Rachna T.
    McBride, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [49] Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX
    Vreeland, Timothy J.
    McAllister, Florencia
    Javadi, Sanaz
    Prakash, Laura R.
    Fogelman, David R.
    Ho, Linus
    Varadhachary, Gauri
    Aloia, Thomas A.
    Vauthey, Jean-Nicolas
    Lee, Jeffrey E.
    Kim, Michael P.
    Katz, Matthew H. G.
    Tzeng, Ching-Wei D.
    PANCREAS, 2019, 48 (06) : 837 - 843
  • [50] Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer
    Rapposelli, Ilario Giovanni
    Casadei-Gardini, Andrea
    Vivaldi, Caterina
    Bartolini, Giulia
    Bernardini, Laura
    Passardi, Alessandro
    Frassineti, Giovanni Luca
    Massa, Valentina
    Cucchetti, Alessandro
    BIOMOLECULES, 2021, 11 (06)
12345